Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)

Hiroko Minatogawa(St. Marianna University School of Medicine), Takako Eguchi Nakajima(St. Marianna University School of Medicine), Kazuhiro Shimomura(Northwestern University), Hitoshi Arioka(Yokohama Rosai Hospital), Takashi Kawaguchi(Higashiosaka College & Higashiosaka Junior College), Junki Endo(Gifu University), Yusuke Inada(Yokohama Rosai Hospital), Naoki Izawa(St. Marianna University School of Medicine), Kazunori Honda(Aichi Cancer Center), Hirotoshi Iihara(Gifu University Hospital), Naoya Hida(Yokohama City Seibu Hospital), Akiko Konomatsu(Nippon Medical School), A Mochizuki(Shizuoka Cancer Center), Kana Akiyama(Shizuoka Cancer Center), Shuichi Nawata(Showa University Northern Yokohama Hospital), Ayako Yokomizo(Kyoto University), Takuhiro Yamaguchi(Tohoku University), Tempei Miyaji(The University of Tokyo), Naoki Furuya(St. Marianna University School of Medicine), Keisuke Mishima(Nippon Medical School), Chikatoshi Katada(Kyoto University), Daisuke Ichikura(Showa University Northern Yokohama Hospital), Yumiko Sone(Aichi Cancer Center), Takashi Ogura(Kanagawa Cardiovascular and Respiratory Center), Yasushi Ohno(Gifu University), Naoya Hashimoto(The University of Osaka), Mitsuhiro Sugawara(Kitasato University), Hajime Morita(St. Marianna University School of Medicine), Takeshi Yanagihara(Nippon Medical School), Ayako Tsuboya
British Journal of Cancer
November 16, 2023
Cited by 18


Related Papers